Treatment of Hepatorenal Syndrome With Terlipressin Plus Albumin vs Albumin
Status:
Suspended
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
Hepatorenal syndrome is a common complication of cirrhotic patients. The prognosis of
patients with HRS is very poor. It have been demonstrated that vasoconstrictors agents
(Terlipressin) plus albumin are effective in the reversal of the treatment. However, previous
studies are pilot studies and they are not able to give information about an improvement in
survival. This comparative randomized study was delineated to test the efficacy of
terlipressin on survival.